Hartaj Singh
Stock Analyst at Oppenheimer
(2.60)
# 1,431
Out of 4,412 analysts
68
Total ratings
51.25%
Success rate
-0.19%
Average return
Main Sectors:
Top Industries:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $3.03 | +197.03% | 4 | Apr 23, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $105 | $65.42 | +60.50% | 4 | Apr 19, 2024 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $13 | $0.83 | +1,469.48% | 2 | Apr 17, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $500 | $397.48 | +25.79% | 8 | Apr 15, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 | $10.78 | +549.35% | 4 | Apr 3, 2024 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $40 | $10.57 | +278.43% | 4 | Mar 8, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | $22 | $12.45 | +76.71% | 1 | Jan 5, 2024 | |
| MRNA Moderna | Upgrades: Outperform | $142 | $107.97 | +31.52% | 4 | Jan 2, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $30 → $25 | $9.00 | +177.78% | 2 | Nov 15, 2023 | |
| OPT Opthea | Maintains: Outperform | $31 → $16 | $3.40 | +370.59% | 3 | Sep 13, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $950 → $1,050 | $883.20 | +18.89% | 5 | Aug 21, 2023 | |
| SPRB Spruce Biosciences | Maintains: Outperform | $8 → $7 | $0.70 | +900.00% | 4 | Aug 18, 2023 | |
| CLLS Cellectis | Reiterates: Outperform | $11 | $2.51 | +339.02% | 3 | Aug 8, 2023 | |
| ELOX Eloxx Pharmaceuticals | Maintains: Outperform | $50 → $55 | $0.81 | +6,725.60% | 3 | Jul 11, 2023 | |
| LIFE aTyr Pharma | Downgrades: Perform | n/a | $1.57 | - | 4 | Jul 5, 2023 | |
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $180 | $128.77 | +39.78% | 4 | May 26, 2023 | |
| ONCT Oncternal Therapeutics | Downgrades: Perform | n/a | $8.29 | - | 3 | Apr 4, 2023 | |
| UTHR United Therapeutics | Maintains: Outperform | $325 → $375 | $233.85 | +60.36% | 2 | Nov 3, 2022 | |
| NBSE NeuBase Therapeutics | Downgrades: Perform | n/a | $0.44 | - | 2 | Oct 21, 2022 | |
| SLS SELLAS Life Sciences Group | Initiates: Outperform | n/a | $1.46 | - | 1 | Nov 1, 2018 | |
| SMMT Summit Therapeutics | Maintains: Outperform | n/a | $3.86 | - | 1 | Jan 26, 2018 |
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $3.03
Upside: +197.03%
Gilead Sciences
Apr 19, 2024
Maintains: Outperform
Price Target: $105
Current: $65.42
Upside: +60.50%
Viracta Therapeutics
Apr 17, 2024
Maintains: Outperform
Price Target: $13
Current: $0.83
Upside: +1,469.48%
Vertex Pharmaceuticals
Apr 15, 2024
Maintains: Outperform
Price Target: $500
Current: $397.48
Upside: +25.79%
Biomea Fusion
Apr 3, 2024
Maintains: Outperform
Price Target: $70
Current: $10.78
Upside: +549.35%
Inovio Pharmaceuticals
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $10.57
Upside: +278.43%
Entrada Therapeutics
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $12.45
Upside: +76.71%
Moderna
Jan 2, 2024
Upgrades: Outperform
Price Target: $142
Current: $107.97
Upside: +31.52%
Astria Therapeutics
Nov 15, 2023
Maintains: Outperform
Price Target: $30 → $25
Current: $9.00
Upside: +177.78%
Opthea
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.40
Upside: +370.59%
Regeneron Pharmaceuticals
Aug 21, 2023
Maintains: Outperform
Price Target: $950 → $1,050
Current: $883.20
Upside: +18.89%
Spruce Biosciences
Aug 18, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $0.70
Upside: +900.00%
Cellectis
Aug 8, 2023
Reiterates: Outperform
Price Target: $11
Current: $2.51
Upside: +339.02%
Eloxx Pharmaceuticals
Jul 11, 2023
Maintains: Outperform
Price Target: $50 → $55
Current: $0.81
Upside: +6,725.60%
aTyr Pharma
Jul 5, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.57
Upside: -
Sarepta Therapeutics
May 26, 2023
Reiterates: Outperform
Price Target: $180
Current: $128.77
Upside: +39.78%
Oncternal Therapeutics
Apr 4, 2023
Downgrades: Perform
Price Target: n/a
Current: $8.29
Upside: -
United Therapeutics
Nov 3, 2022
Maintains: Outperform
Price Target: $325 → $375
Current: $233.85
Upside: +60.36%
NeuBase Therapeutics
Oct 21, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.44
Upside: -
SELLAS Life Sciences Group
Nov 1, 2018
Initiates: Outperform
Price Target: n/a
Current: $1.46
Upside: -
Summit Therapeutics
Jan 26, 2018
Maintains: Outperform
Price Target: n/a
Current: $3.86
Upside: -